Form 4: NeuroOne Medical Technologies Director Acquires Shares and Options

Director Jeffrey S. Mathiesen reports acquisition of NeuroOne Medical Technologies stock and options through grant and vesting.

Summary

• On February 14, 2025, Jeffrey S. Mathiesen, a director of NeuroOne Medical Technologies Corp, acquired 27,778 shares of common stock and options to purchase 17,025 shares.
• The common stock was acquired through a grant of restricted stock units, which vest in 12 equal monthly installments over a one-year period.
• The options have an exercise price of $1.20 and also vest in 12 equal monthly installments over a one-year period, expiring on February 14, 2035.
• Following these transactions, Mathiesen directly owns 114,414 shares of common stock and options for 17,025 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider ownership can be a good sign, but the transactions are part of a standard compensation package.

Positives

• The acquisition of shares and options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The acquisition of shares and options by a director may increase shareholder confidence.

Key Dates

Keywords

NeuroOne Medical Technologies, Director, Form 4, Stock Options, Restricted Stock Units, NMTC, Beneficial Ownership